Kalytera Therapeutics, Inc. announced the formation of a Strategic & Scientific Advisory Board with three key appointments: Professor Joseph Lynch, Ph.D.; Dr. Li Zhang; and Professor Hanns Ulrich Zeilhofer. The Strategic and Scientific Advisory Board will work closely with Kalytera’s management to advance the Company’s novel cannabinoid-based technology for the treatment of acute and chronic pain, identify new applications for Kalytera’s cannabinoid technology, and provide insight regarding new cannabinoid-based technologies to complement the Company’s pipeline.